Clinical Trials Browser

OTHER × Ipilimumab × Clear all

NCT03918252 2026-06-05

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Phase 2 Active not recruiting

Other solid neoplasmThoracic

Mesothelioma

NCT03949153 2026-06-05

CRIRIN

Phase 1/2 Completed

Melanoma

NCT07510334 2026-06-05

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03958383 2026-06-03

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Phase 1/2 Terminated

8 enrolled 12 charts

Melanoma

NCT04042753 2026-06-02

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Phase 2 Completed

Pituitary Diseases, Pituitary Neoplasms

NCT02210117 2026-06-01

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Phase EARLY_PHASE1 Active not recruiting

Carcinoma, Renal Cell

NCT02693535 2026-05-29

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT04465643 2026-05-29

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Phase 1 Completed

Nerve Sheath Neoplasms

NCT03017820 2026-05-28

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Phase 2 Active not recruiting

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05498792 2026-05-22

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Phase EARLY_PHASE1 Recruiting

Melanoma

NCT07355205 2026-05-22

FLINN

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07603856 2026-05-22

REVIVE

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02696993 2026-05-20

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04388852 2026-05-20

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Phase 1 Active not recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

NCT04141644 2026-05-19

Osi+Ipi

Phase 1 Active not recruiting

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT05779423 2026-05-19

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT06365619 2026-05-18

NeoRelapse

Phase 2 Recruiting

Melanoma

NCT06712927 2026-05-18

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Phase 2 Recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT07394062 2026-05-18

ALCG-01

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03600155 2026-05-15

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04003649 2026-05-14

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Phase 1 Active not recruiting

Glioblastoma

NCT06708949 2026-05-14

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT07587827 2026-05-14

ODI-2001-01

Phase 1 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT04464759 2026-05-11

LIMIT

Phase 1/2 Recruiting

Melanoma

NCT07128680 2026-05-11

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase 1 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03122522 2026-05-06

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Phase 2 Active not recruiting

Melanoma

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1 Not yet recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT05012254 2026-05-05

NIVIPI-Brain

Phase 2 Active not recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT05144529 2026-05-05

TOP2101

Phase 2 Terminated

19 enrolled 16 charts

Lung Cancer Metastatic

NCT06941857 2026-05-05

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT05327686 2026-05-04

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT07166406 2026-05-04

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07188896 2026-05-01

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT03799445 2026-04-30

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Phase 2 Terminated

37 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT04472767 2026-04-30

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07075120 2026-04-30

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03521830 2026-04-29

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Basal Cell

NCT03789110 2026-04-28

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Phase 2 Active not recruiting

30 enrolled 15 charts

Breast Neoplasms

NCT05014776 2026-04-28

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase 2 Completed

17 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT06889493 2026-04-28

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Phase 1 Recruiting

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05361720 2026-04-27

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Phase 2 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02812524 2026-04-24

Ipilimumab for Head and Neck Cancer Patients

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05219435 2026-04-24

VEXILLUM

Phase 2 Completed

Neoplasm Metastasis

NCT05341349 2026-04-23

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1 Terminated

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT04080804 2026-04-22

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07504796 2026-04-21

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Phase 4 Recruiting

Melanoma

NCT07532902 2026-04-16

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Phase 1 Recruiting

Carcinoma, Transitional Cell

NCT03776487 2026-04-15

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Clinical Stage 0 Gastric Cancer AJCC v8

NCT06049576 2026-04-15

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Phase 1 Active not recruiting

Carcinoma, Renal Cell